BRAF Non-V600

CI-VAR-00002992Explore in graph →CIViC 2408

Curated evidence

Evidence by cancer (5 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–5 of 5 evidence items across 5 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Erdheim-Chester Disease1
BRAF Non-V600	Cobimetinib	Predictive	B	Supports Sensitivity Response	4	submitted	EID11298 In an open-label, phase II trial, 18 patients with histiocytosis, including 12 patients with Erdheim-Chester disease with one patient having a non-V600 BRAF mutation, of any mutational status were enr… (full text at CIViC) PMID 30867592 · Diamond et al., 2019 · Open in CIViC	civic
Langerhans Cell Histiocytosis1
BRAF Non-V600	Cobimetinib	Predictive	B	Supports Sensitivity Response	4	submitted	EID11299 In an open-label, phase II trial, 18 patients with histiocytosis, including two patients with Langerhans cell histiocytosis, with one patient having a non-V600 BRAF mutation, of any mutational status … (full text at CIViC)

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Malignant Colorectal Neoplasm1
BRAF Non-V600	(prognostic)	Prognostic	B	Supports Better Outcome	5	accepted	EID3046 This study of 9,643 patients characterized clinical implications of non-V600 BRAF mutations in metastatic CRC. Of the patients with metastatic CRC that underwent NGS testing, 208 patients had non-V60… (full text at CIViC) PMID 28486044 · Jones et al., 2017 · Open in CIViC	civic

Melanoma1
BRAF V600R AND BRAF Non-V600	Dabrafenib + TrametinibCombination	Predictive	B	Supports Sensitivity Response	1	submitted	EID11308 In this phase 1/2, open-label study 247 patients with metastatic melanoma and BRAF V600 mutations V600 (only one patient with a non-V600E/V600K with a BRAF V600R) were enrolled. Part 1 evaluated the p… (full text at CIViC) PMID 23020132 · Flaherty et al., 2012 · Open in CIViC	civic

Solid Neoplasm1
BRAF Non-V600	Trametinib	Predictive	B	Does Not Support Sensitivity Response	4	accepted	EID7855 In a phase II basket trial (NCI-MATCH), patients with solid tumors or hematologic malignancies harboring BRAF non-V600 mutations were treated with trametinib. Among 50 patients assigned, 32 were eligi… (full text at CIViC) PMID 31924734 · Johnson et al., 2020 · Open in CIViC	civic